相似文献
1
Using immunoproteomics to identify tumor-associated antigens (TAAs) as biomarkers in cancer immunodiagnosis.
Autoimmun Rev. 2013 Oct;12(12):1123-8. doi: 10.1016/j.autrev.2013.06.015. Epub 2013 Jun 24.
2
Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis.
Autoimmun Rev. 2011 Apr;10(6):331-5. doi: 10.1016/j.autrev.2010.12.002. Epub 2010 Dec 15.
3
Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer.
Scand J Immunol. 2009 Jan;69(1):57-63. doi: 10.1111/j.1365-3083.2008.02195.x.
4
Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis.
Expert Rev Mol Diagn. 2015 Jun;15(6):829-52. doi: 10.1586/14737159.2015.1035713. Epub 2015 May 9.
5
Evaluation of diagnostic value in using a panel of multiple tumor-associated antigens for immunodiagnosis of cancer.
J Immunol Res. 2014;2014:512540. doi: 10.1155/2014/512540. Epub 2014 Apr 13.
6
Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma.
Clin Immunol. 2014 May-Jun;152(1-2):127-39. doi: 10.1016/j.clim.2014.03.007. Epub 2014 Mar 22.
7
Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
J Cell Biochem. 2019 Mar;120(3):3091-3100. doi: 10.1002/jcb.27497. Epub 2018 Nov 28.
8
Tumor-Associated Antigens (TAAs) for the Serological Diagnosis of Osteosarcoma.
Front Immunol. 2021 Apr 30;12:665106. doi: 10.3389/fimmu.2021.665106. eCollection 2021.
9
Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
Cancer Sci. 2021 Feb;112(2):537-549. doi: 10.1111/cas.14732. Epub 2020 Dec 3.
10
Exploring the immunoproteome for ovarian cancer biomarker discovery.
Int J Mol Sci. 2011 Jan 14;12(1):410-28. doi: 10.3390/ijms12010410.
引用本文的文献
1
Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review.
Immunother Adv. 2025 Jan 27;5(1):ltae005. doi: 10.1093/immadv/ltae005. eCollection 2025.
2
Potential and development of cellular vesicle vaccines in cancer immunotherapy.
Discov Oncol. 2025 Jan 15;16(1):48. doi: 10.1007/s12672-025-01781-3.
3
Targeting APE1: Advancements in the Diagnosis and Treatment of Tumors.
Protein Pept Lett. 2025;32(1):18-33. doi: 10.2174/0109298665338519241114103223.
4
A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma.
Cancer Cell Int. 2023 Nov 16;23(1):273. doi: 10.1186/s12935-023-03107-1.
5
Identification and validation of a novel tumor driver gene signature for diagnosis and prognosis of head and neck squamous cell carcinoma.
Front Mol Biosci. 2022 Oct 20;9:912620. doi: 10.3389/fmolb.2022.912620. eCollection 2022.
6
Editorial: Tumor-associated antigens and their autoantibodies, from discovering to clinical utilization.
Front Oncol. 2022 Jul 20;12:970623. doi: 10.3389/fonc.2022.970623. eCollection 2022.
7
Rapid, site-specific labeling of "off-the-shelf" and native serum autoantibodies with T cell-redirecting domains.
Sci Adv. 2022 May 6;8(18):eabn4613. doi: 10.1126/sciadv.abn4613.
8
Establishment of a Novel Mouse Hepatocellular Carcinoma Model for Dynamic Monitoring of Tumor Development by Bioluminescence Imaging.
Front Oncol. 2022 Feb 17;12:794101. doi: 10.3389/fonc.2022.794101. eCollection 2022.
9
Identification and validation of serum autoantibodies in children with B-cell acute lymphoblastic leukemia by serological proteome analysis.
Proteome Sci. 2022 Feb 2;20(1):3. doi: 10.1186/s12953-021-00184-w.
10
A novel immunodiagnosis panel for hepatocellular carcinoma based on bioinformatics and the autoantibody-antigen system.
Cancer Sci. 2022 Feb;113(2):411-422. doi: 10.1111/cas.15217. Epub 2021 Dec 14.
本文引用的文献
1
Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis.
J Proteome Res. 2013 Apr 5;12(4):1789-96. doi: 10.1021/pr3011342. Epub 2013 Mar 15.
2
Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma.
J Proteome Res. 2011 Jun 3;10(6):2863-72. doi: 10.1021/pr200141c. Epub 2011 May 3.
3
Hallmarks of cancer: the next generation.
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
4
Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis.
Autoimmun Rev. 2011 Apr;10(6):331-5. doi: 10.1016/j.autrev.2010.12.002. Epub 2010 Dec 15.
5
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors.
Expert Rev Mol Diagn. 2010 Apr;10(3):321-8. doi: 10.1586/erm.10.12.
6
Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma.
Cancer Lett. 2010 Mar 1;289(1):32-9. doi: 10.1016/j.canlet.2009.07.016. Epub 2009 Aug 15.
7
Clinical proteomics in cancer research-promises and limitations of current two-dimensional gel electrophoresis.
Curr Med Chem. 2008;15(23):2393-400. doi: 10.2174/092986708785909102.
8
Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma.
J Proteome Res. 2008 Sep;7(9):4004-12. doi: 10.1021/pr800273h. Epub 2008 Aug 2.
9
Autoantibodies to tumor-associated antigens: reporters from the immune system.
Immunol Rev. 2008 Apr;222:328-40. doi: 10.1111/j.1600-065X.2008.00611.x.
10
CIP2A inhibits PP2A in human malignancies.
Cell. 2007 Jul 13;130(1):51-62. doi: 10.1016/j.cell.2007.04.044.
Zotero 插件